Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 818
- Registration Number
- NCT04305496
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 69
- Registration Number
- NCT04300790
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸Hospital Universitario de Leon, León, Spain
🇪🇸Hospital Beata María Ana, Madrid, Spain
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Beta Pharma (Suzhou) Co., Ltd.
- Target Recruit Count
- 224
- Registration Number
- NCT04282031
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Herui Yao
- Target Recruit Count
- 210
- Registration Number
- NCT04263298
- Locations
- 🇨🇳
Affiliated Hospital of Guangdong Medical University, Zhangjiang, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
🇨🇳Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-02-10
- Target Recruit Count
- 760
- Registration Number
- NCT04258163
- Locations
- 🇨🇳
First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04256941
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT04247126
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT04224272
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸UCLA Hematology/Oncology Parkside, Santa Monica, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT04214288
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 325
- Registration Number
- NCT04191499
- Locations
- 🇪🇸
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
🇪🇸Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain
🇪🇸Hospital del Mar; Servicio de Oncologia, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.